Gabelli Funds LLC Has $41.23 Million Stake in Stryker Co. (NYSE:SYK)

Gabelli Funds LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,524 shares of the medical technology company’s stock after selling 1,250 shares during the period. Gabelli Funds LLC’s holdings in Stryker were worth $41,234,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Jump Financial LLC acquired a new position in Stryker during the 4th quarter worth $4,204,000. Kane Investment Management Inc. acquired a new stake in Stryker in the 4th quarter valued at $749,000. Guggenheim Capital LLC increased its position in shares of Stryker by 7.0% during the 4th quarter. Guggenheim Capital LLC now owns 7,579 shares of the medical technology company’s stock worth $2,729,000 after purchasing an additional 499 shares during the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in Stryker in the 4th quarter valued at $7,238,000. Finally, Comgest Global Investors S.A.S. lifted its holdings in Stryker by 48.7% during the 4th quarter. Comgest Global Investors S.A.S. now owns 68,672 shares of the medical technology company’s stock worth $24,725,000 after purchasing an additional 22,496 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

SYK opened at $353.45 on Tuesday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market capitalization of $134.91 billion, a PE ratio of 45.55, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business’s 50-day moving average is $374.63 and its two-hundred day moving average is $373.58.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm posted $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.95%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. The Goldman Sachs Group set a $422.00 price objective on Stryker in a research report on Tuesday, March 4th. Wells Fargo & Company upped their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Finally, Barclays boosted their price target on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $423.05.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.